Skip to main content
OpenTrials

Clinical trial condition

Melanoma

Explore clinical trials studying Melanoma. Study availability and eligibility vary by location and protocol.

1,012 public trials 175 recruiting studies
Refine in advanced search Browse all conditions

Melanoma trial results

Completed

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

NCT05665595

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • Moores Cancer Center ( Site 0116) La Jolla, California, United States
  • The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123) Los Angeles, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131) Los Angeles, California, United States
  • California Pacific Medical Center - Pacific Campus ( Site 0111) San Francisco, California, United States
View all 205 locations
View Trial Details
Completed

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

NCT04370704

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • H Lee Moffitt Cancer Center and Research Tampa, Florida, United States
  • University of Iowa Iowa City, Iowa, United States
View all 17 locations
View Trial Details
Completed

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

NCT04577807

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • HonorHealth Research Institute Scottsdale, Arizona, United States
  • Orlando Health U7 Health Cancer Center Orlando, Florida, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • Cancer Treatment Centers of America Zion, Illinois, United States
View Trial Details
Completed

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

NCT04305041

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • The Angeles Clinic and Research Institute ( Site 1009) Los Angeles, California, United States
  • UCLA Hematology & Oncology ( Site 1004) Los Angeles, California, United States
  • Providence Saint John's Health Center ( Site 1010) Santa Monica, California, United States
  • University of Colorado, Anschutz Cancer Pavilion ( Site 1012) Aurora, Colorado, United States
View all 36 locations
View Trial Details
Completed

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

NCT03715205

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +18 more
Locations
  • Nizam's Institute of Medical Sciences ( Site 0011) Hyderabad, Andhra Pradesh, India
  • Artemis Health Institute ( Site 0007) Gurgaon, Haryana, India
  • Tata Memorial Hospital [M] ( Site 0005) Mumbai, Maharashtra, India
  • Kokilaben Ben Dhirubhai Ambani Hosp & Med Res Inst. ( Site 0001) Mumbai, Maharashtra, India
View Trial Details
Completed

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989

Conditions
Advanced Solid Tumor, Blood Protein Disorders, Bronchial Neoplasms, +62 more
Locations
  • UCLA Department of Medicine - Hematology/Oncology Los Angeles, California, United States
  • Mayo Clinic Jacksonville - PPDS Jacksonville, Florida, United States
  • Goshen Health System Goshen, Indiana, United States
  • Holden Comprehensive Cancer Center Iowa City, Iowa, United States
View all 22 locations
View Trial Details

Related conditions